Trans Sodium Crocetinate

DRUG3 trials

Sponsors

Diffusion Pharmaceuticals Inc

Conditions

Healthy Volunteers With Induced HypoxiaInterstitial Lung DiseaseSARS-CoV-2 (Covid19)

Phase 1

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects

CompletedNCT04573322

Diffusion Pharmaceuticals IncSARS-CoV-2 (Covid19)

Start: 2020-09-10End: 2021-04-29Updated: 2022-04-14

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude

CompletedNCT05036980

Diffusion Pharmaceuticals IncHealthy Volunteers With Induced Hypoxia

Start: 2021-11-09End: 2022-04-10Updated: 2022-04-13

Phase 2

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

TerminatedNCT05079126

Diffusion Pharmaceuticals IncInterstitial Lung Disease

Start: 2021-12-02End: 2022-05-27Updated: 2022-08-10